Press Releases
Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Europe Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms
Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Australia Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms
Relmada Therapeutics Announces $6.9 Million Private Placement
Relmada Therapeutics Appoints Dr. Maurizio Fava as Chair of the Dextromethadone Scientific Advisory Board for its Depression Program
Dr. Ottavio Vitolo Appointed Executive Clinical Advisor at Relmada Therapeutics
Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of Directors
Relmada Therapeutics Announces Settlement of Legal Action with Laidlaw & Company
Relmada Announces FDA Fast Track Designation for d-Methadone for Adjunctive Treatment of Major Depressive Disorder
Relmada Therapeutics to Participate in the 2nd Annual Disruptive Growth & Healthcare Conference
Relmada Therapeutics to Participate in BIO CEO and Investor Conference
